Group items tagged

Market Overview: Next-generation antibody therapeutics includes the use of new improvised therapeutic antibody to form innovative medicines for treating various diseases. Next-generation antibody therapeutics is developed clinically by pharmaceutical and biotechnology companies for several diseases. The Next Generation Antibody Therapeutics Market size was worth $ XX million in 2018 and is forecasted to reach $ XX million by 2026, expected to grow at a high CAGR during the forecast period 2019-2026. Market Dynamics: The Next Generation Antibody Therapeutics Market is growing due to several factors such as rising incidence of chronic diseases, increasing emergence of antibody technology, new drug discovery, large number of government initiatives, and growing research and development activities for new therapies. Rising prevalence of chronic disease such as cancer, asthma, diabetes and COPD are boosting the growth of the next generation antibody therapeutics market. For instance, according to National Cancer Institute in 2018, in United States, an estimated 1,735,350 new cases of cancer will be diagnosed and 609,640 people will die from the disease. The development of next-generation monoclonal antibodies has expanded beyond oncology into all therapeutic areas. For instance, ADCs were initially focused primarily on cancer, but Genentech has applied to infectious diseases, leading to the discovery and development of THIOMAB antibiotic conjugates (TACs) for the treatment of methicillin-resistant Staphylococcus aureus (MRSA). The technological advancements in antibody therapeutics have led to the development of more efficient antibody therapeutics, hence, driving the growth in the next-generation antibody therapeutics market. However, stringent government regulation, high cost and time required for research and development activities are some of the factors hindering the growth for global next-generation antibody therapeutics market. Market Segmentation: Based o

Dr. Vinod Raina Fortis Gurgaon strives to bring the best and latest in cancer care, establishing himself as a top oncologist for surgical oncology in India.

Best haemato oncologist in India offers a comprehensive range of state-of-the-art diagnostic and treatment facilities for cancer patients of all age groups, all conveniently located under one roof.

As a bone marrow transplant surgeon in Gurugram, patient can get Dr. Rahul Bhargava appointment India collaborates closely with patients and their families to manage cases, focusing on providing radiation therapy.

India has emerged as a hub for low-cost cancer treatment, attracting patients from around the world seeking affordable and high-quality healthcare.

الدكتور راجاسوندارام إس، جراح الأورام الأعلى في مستشفى تشيناي العالمي، هو رائد مشهور في مجال جراحة الأورام في جنوب الهند.